• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

非肌层浸润性膀胱肿瘤的膀胱内治疗

[Intravesical therapy of non-muscle invasive bladder tumors].

作者信息

Vom Dorp F, Tschirdewahn S, Lümmen G

机构信息

Klinik und Poliklinik für Urologie, Universitätsklinikum Essen, Hufelandstr. 55, 45122 Essen, Deutschland.

出版信息

Urologe A. 2012 Feb;51(2):257-64. doi: 10.1007/s00120-011-2775-4.

DOI:10.1007/s00120-011-2775-4
PMID:22331075
Abstract

Intravesical therapy of non-muscle invasive bladder tumors has a long tradition. With regard to low grade tumors prevention of tumor recurrence remains the main endpoint, whereas in high grade tumors prevention of tumor progression is the main aim of intravesical treatment. The following article critically discusses these aspects of non-muscle invasive bladder tumors.

摘要

非肌层浸润性膀胱肿瘤的膀胱内治疗有着悠久的历史。对于低级别肿瘤，预防肿瘤复发仍是主要终点，而对于高级别肿瘤，预防肿瘤进展是膀胱内治疗的主要目标。以下文章对非肌层浸润性膀胱肿瘤的这些方面进行了批判性讨论。

相似文献

1
[Intravesical therapy of non-muscle invasive bladder tumors].非肌层浸润性膀胱肿瘤的膀胱内治疗
Urologe A. 2012 Feb;51(2):257-64. doi: 10.1007/s00120-011-2775-4.
2
Management of high-risk non-muscle invasive bladder cancer.高危非肌层浸润性膀胱癌的管理
Minerva Urol Nefrol. 2012 Dec;64(4):255-60.
3
[Non-muscle-invasive transitional cell carcinoma. Is BCG still a necessary part of treatment?].[非肌层浸润性移行细胞癌。卡介苗仍然是治疗的必要组成部分吗？]
Urologe A. 2010 Oct;49(10):1274-6. doi: 10.1007/s00120-010-2396-3.
4
[International Consensus Panel--treatment strategies for superficial bladder cancer].[国际共识小组——浅表性膀胱癌的治疗策略]
Aktuelle Urol. 2006 Sep;37(5):320-3; discussion 322-3. doi: 10.1055/s-2006-951427.
5
Phase I trial of intravesical Bacillus Calmette-Guérin combined with intravenous pembrolizumab in recurrent or persistent high-grade non-muscle-invasive bladder cancer after previous Bacillus Calmette-Guérin treatment.卡介苗联合静脉注射派姆单抗治疗卡介苗治疗后复发或持续性高级别非肌层浸润性膀胱癌的 I 期临床试验。
World J Urol. 2021 Oct;39(10):3807-3813. doi: 10.1007/s00345-021-03716-3. Epub 2021 May 8.
6
Anti-inflammatory use may not negatively impact oncologic outcomes following intravesical BCG for high-grade non-muscle-invasive bladder cancer.对于高级别非肌层浸润性膀胱癌，在膀胱内灌注卡介苗后进行抗炎治疗可能不会对肿瘤学结局产生负面影响。
World J Urol. 2017 Jan;35(1):105-111. doi: 10.1007/s00345-016-1853-z. Epub 2016 May 18.
7
Intra-arterial chemotherapy combined with intravesical chemotherapy compared with intravesical BCG immunotherapy retrospectively in high-risk non-muscle-invasive bladder cancer after transurethral resection of the bladder tumor.经尿道膀胱肿瘤切除术治疗后高危非肌层浸润性膀胱癌患者行动脉内化疗联合膀胱内化疗与膀胱内卡介苗免疫治疗的回顾性比较
J Cancer Res Clin Oncol. 2021 Jun;147(6):1781-1788. doi: 10.1007/s00432-020-03453-x. Epub 2020 Nov 22.
8
Editorial comment on: Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder cancer.关于以下内容的编辑评论：与短期膀胱内化疗及卡介苗（BCG）短期治疗相比，长期膀胱内辅助化疗可进一步降低非肌层浸润性膀胱癌患者的复发率。
Eur Urol. 2007 Oct;52(4):1129-30. doi: 10.1016/j.eururo.2007.02.064.
9
Low dose BCG regimen in T1 transitional cell carcinoma of the bladder: long term results.低剂量卡介苗方案治疗膀胱T1期移行细胞癌的长期结果
J Egypt Natl Canc Inst. 2009 Jun;21(2):151-5.
10
[Comparison of the effectiveness between long-term instillation of mitomycin C and short-term prophylaxis with MMC or bacille Calmette-Guérin. Study of patients with non-muscle-invasive urothelial cancer of the urinary bladder].[膀胱非肌层浸润性尿路上皮癌患者长期丝裂霉素C灌注与丝裂霉素C或卡介苗短期预防效果的比较研究]
Urologe A. 2008 May;47(5):608-15. doi: 10.1007/s00120-008-1671-z.

引用本文的文献

1
[Secondary prevention in patients with superficial urothelial carcinoma].[浅表性尿路上皮癌患者的二级预防]
Urologe A. 2015 Jul;54(7):992-7. doi: 10.1007/s00120-015-3839-7.
2
[Visual diagnosis while performing transurethral resection of bladder tumors: power or myth?].
Urologe A. 2014 Nov;53(11):1639-43. doi: 10.1007/s00120-014-3585-2.

本文引用的文献

1
[Urothelial carcinoma of the bladder: evaluation by combined endoscopy and urine cytology: is incontrovertible assessment possible?].[膀胱尿路上皮癌：联合内镜检查与尿液细胞学检查的评估：能否进行确凿的评估？]
Urologe A. 2011 Jun;50(6):702-5. doi: 10.1007/s00120-010-2502-6.
2
Sequential intravesical chemoimmunotherapy with mitomycin C and bacillus Calmette-Guérin and with bacillus Calmette-Guérin alone in patients with carcinoma in situ of the urinary bladder: results of an EORTC genito-urinary group randomized phase 2 trial (30993).序贯膀胱内顺铂化疗联合卡介苗与单纯卡介苗免疫治疗表浅膀胱癌的随机 2 期 EORTC 泌尿生殖系肿瘤研究组临床试验（30993）
Eur Urol. 2011 Mar;59(3):438-46. doi: 10.1016/j.eururo.2010.11.038. Epub 2010 Dec 7.
3
Clinical outcome of primary versus secondary bladder carcinoma in situ.原发性与继发性膀胱癌原位的临床转归。
J Urol. 2010 Aug;184(2):464-9. doi: 10.1016/j.juro.2010.03.134. Epub 2010 Jun 17.
4
Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder.EORTC 泌尿生殖系统肿瘤组随机 3 期研究 30911 的长期疗效结果，比较表柔比星、卡介苗和卡介苗联合异烟肼膀胱内灌注治疗中高危期 TaT1 尿路上皮膀胱癌患者的疗效。
Eur Urol. 2010 May;57(5):766-73. doi: 10.1016/j.eururo.2009.12.024. Epub 2009 Dec 18.
5
[Urine-based cytological diagnosis against the background of the new histopathological classification].
Urologe A. 2009 Jun;48(6):615-8. doi: 10.1007/s00120-009-1990-8.
6
An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer.一项针对非肌层浸润性膀胱癌患者，比较膀胱内注射丝裂霉素C与卡介苗的随机研究长期结果的个体患者数据荟萃分析。
Eur Urol. 2009 Aug;56(2):247-56. doi: 10.1016/j.eururo.2009.04.038. Epub 2009 Apr 24.
7
Is maintenance Bacillus Calmette-Guérin really necessary?维持性卡介苗真的有必要吗？
Eur Urol. 2008 Nov;54(5):971-3. doi: 10.1016/j.eururo.2008.06.062. Epub 2008 Jun 25.
8
The schedule and duration of intravesical chemotherapy in patients with non-muscle-invasive bladder cancer: a systematic review of the published results of randomized clinical trials.非肌层浸润性膀胱癌患者膀胱内化疗的方案及疗程：对随机临床试验已发表结果的系统评价
Eur Urol. 2008 Apr;53(4):709-19. doi: 10.1016/j.eururo.2008.01.015. Epub 2008 Jan 15.
9
Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials.卡介苗与化疗用于膀胱原位癌患者膀胱内治疗的比较：随机临床试验已发表结果的荟萃分析
J Urol. 2005 Jul;174(1):86-91; discussion 91-2. doi: 10.1097/01.ju.0000162059.64886.1c.
10
A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials.术后单次即刻灌注化疗可降低Ta T1期膀胱癌患者的复发风险：一项对已发表的随机临床试验结果的荟萃分析。
J Urol. 2004 Jun;171(6 Pt 1):2186-90, quiz 2435. doi: 10.1097/01.ju.0000125486.92260.b2.